Nephro-Urology Monthly

Published by: Kowsar

Lessons From the KK-Ay Mouse, a Spontaneous Animal Model for the Treatment of human Type 2 Diabetic Nephropathy

Yasuhiko Tomino 1 , *
Author Information
1 Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
Article information
  • Nephro-Urology Monthly: June 01, 2012, 4 (3); 524-529
  • Published Online: June 20, 2012
  • Article Type: Review Article
  • Received: July 27, 2011
  • Revised: September 6, 2011
  • Accepted: September 15, 2011
  • DOI: 10.5812/numonthly.1954

To Cite: Tomino Y. Lessons From the KK-Ay Mouse, a Spontaneous Animal Model for the Treatment of human Type 2 Diabetic Nephropathy, Nephro-Urol Mon. 2012 ; 4(3):524-529. doi: 10.5812/numonthly.1954.

Abstract
Copyright © 2012, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Characteristics of KK-Ay Mouse
4. Approaches to the Treatment of Type 2 Diabetic Nephropathy
Acknowledgements
Footnotes
References
  • 1. Kondo K, Nozawa K, Tomita T, Ezaki K. Inbred strains resulting from Japanese mice. Bull Exp Anim. 1967; 6: 107-12
  • 2. Taketomi S, Ikeda H, Ishikawa E, Iwatsuka H. Determination of overall insulin sensitivity in diabetic mice, KK. Horm Metab Res. 1982; 14(1): 14-8[DOI][PubMed]
  • 3. Matsuo T, Shino A. Induction of diabetic alterations by goldthioglucose-obesity in KK,ICR and C57BL mice. Diabetologia. 1972; 8(6): 391-7[DOI][PubMed]
  • 4. Ikeda H. KK mouse. Diabetes Res Clin Pract. 1994; 24-6[DOI][PubMed]
  • 5. Nishimura M. Breeding of mouse strains for diabetes mellitus. Exp Anim. 1969; 18: 147-57
  • 6. Tomino Y. Lessons from the spontaneous mouse models for treatment of type 2 diabetic nephropathy and IgA nephropathy. Juntendo Med J. 2009; 55: 228-34
  • 7. Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton). 2006; 11(1): 29-35[DOI][PubMed]
  • 8. Hishiki T, Shirato I, Takahashi Y, Funabiki K, Horikoshi S, Tomino Y. Podocyte injury predicts prognosis in patients with iga nephropathy using a small amount of renal biopsy tissue. Kidney Blood Press Res. 2001; 24(2): 99-104[DOI][PubMed]
  • 9. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int. 2002; 61(4): 1475-85[DOI][PubMed]
  • 10. Macedo CS, Lerco MM, Capelletti SM, Silva RJ, Pinheiro Dde O, Spadella CT. Reduction of podocytes number in late diabetic alloxan nephropathy: prevention by glycemic control. Acta Cir Bras. 2007; 22(5): 337-41[DOI][PubMed]
  • 11. Aoki T, Kaneko S, Tanimoto M, Gohda T, Hagiwara S, Murakoshi M, et al. Identification of quantitative trait loci for diabetic nephropathy in KK-Ay/Ta mice. J Nephrol. 2011; [PubMed]
  • 12. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001; 44(2): 129-46[DOI][PubMed]
  • 13. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun. 1999; 257(2): 251-8[DOI][PubMed]
  • 14. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 2002; 61(3): 939-50[DOI][PubMed]
  • 15. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism. 2007; 56(2): 160-7[DOI][PubMed]
  • 16. Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Ohara I, Toyoda H, et al. Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Diabetes Res Clin Pract. 2009; 83(2): 183-9[DOI][PubMed]
  • 17. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010; 376(9752): 1543-51[DOI][PubMed]
  • 18. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007; 27(6): 605-14[DOI][PubMed]
  • 19. Yamazaki T, Tanimoto M, Gohda T, Ohara I, Hagiwara S, Murakoshi M, et al. Combination effects of enalapril and losartan on lipid peroxidation in the kidneys of KK-Ay/Ta mice. Nephron Exp Nephrol. 2009; 113(2)-76[DOI][PubMed]
  • 20. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med. 2007; 24(5): 486-93[DOI][PubMed]
  • 21. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006; 69(1): 105-13[DOI][PubMed]
  • 22. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 2007; 72(1): 45-52[DOI][PubMed]
  • 23. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol. 2007; 18(6): 1789-95[DOI][PubMed]
  • 24. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinge M, Schwarz U, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol. 2004; 286(3)-33[DOI][PubMed]
  • 25. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 1998; 53(6): 1696-705[DOI][PubMed]
  • 26. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol. 2001; 158(5): 1733-41[DOI][PubMed]
  • 27. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004; 89-90(1-5): 387-92[PubMed]
  • 28. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007; 282(41): 29821-30[DOI][PubMed]
  • 29. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, et al. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 2001; 60(1): 87-95[DOI][PubMed]
  • 30. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A. 2008; 105(41): 15896-901[DOI][PubMed]
  • 31. Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, et al. Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. Nephron Exp Nephrol. 2011; 117(4)-32[DOI][PubMed]
  • 32. Zhang M, Hagiwara S, Matsumoto M, Gu L, Tanimoto M, Nakamura S, et al. Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: involvement of anti-inflammation and antioxidative stress. Metabolism. 2006; 55(12): 1590-8[DOI][PubMed]
  • 33. Hagiwara S, Makita Y, Gu L, Tanimoto M, Zhang M, Nakamura S, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant. 2006; 21(3): 605-15[DOI][PubMed]
  • 34. Lee CC, Sharp SJ, Wexler DJ, Adler AI. Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial. Diabetes Care. 2010; 33(7): 1454-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments